Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 16/20 | 0.66 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.59 |
| ▸ | AHCYL1 | O43865 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.39 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluoro-Neplanocin A SCHEMBL9215628 | 0.80 | AHCY (1.00) | AHCYSMN1; SMN2 | |
| Fluoro-Neplanocin A SCHEMBL9214745 | 0.80 | AHCY (1.00) | AHCYSMN1; SMN2 | |
| Fluoro-Neplanocin A SCHEMBL9214735 | 0.80 | AHCY (1.00) | AHCYSMN1; SMN2 | |
| SCHEMBL10051882 | 0.78 | AHCY (0.52) | AHCYEZH2AHCYL1SMN1; SMN2DNMT1 | |
| SCHEMBL9221061 | 0.74 | AHCY (0.70) | AHCYSMN1; SMN2 | |
| SCHEMBL9221056 | 0.74 | AHCY (0.70) | AHCYSMN1; SMN2 | |
| 3-Deazaneplanocin A SCHEMBL23683021 | 0.74 | AHCY (1.00) | AHCYEZH2AHCYL1SMN1; SMN2DNMT1 | |
| 3-Deazaneplanocin A SCHEMBL1521229 | 0.74 | AHCY (1.00) | AHCYEZH2AHCYL1SMN1; SMN2DNMT1 | |
| 3-Deazaneplanocin A SCHEMBL12321313 | 0.74 | AHCY (1.00) | AHCYEZH2AHCYL1SMN1; SMN2DNMT1 | |
| 3-Deazaneplanocin A SCHEMBL12280318 | 0.74 | AHCY (1.00) | AHCYEZH2AHCYL1SMN1; SMN2DNMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2522352-B1 | Methods for stem cells modulation | AGENCY SCIENCE TECH & RES (SG) | 2017-01-11 | — | — | EP | disclosed |
| EP-2522352-B1 | Methods for stem cells modulation | AGENCY SCIENCE TECH & RES (SG) | 2017-01-11 | — | — | EP | disclosed |
| US-20160015693-A1 | METHODS AND COMPOUNDS FOR PREVENTING AND TREATING A TUMOUR | AGENCY SCIENCE TECH & RES (SG) | 2016-01-21 | — | — | US | disclosed |
| US-8969313-B2 | Methods and compounds for preventing and treating a tumour | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-03-03 | — | — | US | disclosed |
| EP-1993553-B1 | METHODS FOR CANCER THERAPY AND STEM CELL MODULATION | AGENCY SCIENCE TECH & RES (SG) | 2013-05-08 | — | — | EP | disclosed |
| EP-1993553-B1 | METHODS FOR CANCER THERAPY AND STEM CELL MODULATION | AGENCY SCIENCE TECH & RES (SG) | 2013-05-08 | — | — | EP | disclosed |
| EP-2522352-A1 | Methods for cancer therapy and stem cell modulation | Agency for Science, Technology and Research (SG) | 2012-11-14 | — | — | EP | disclosed |
| EP-2522352-A1 | Methods for cancer therapy and stem cell modulation | Agency for Science, Technology and Research (SG) | 2012-11-14 | — | — | EP | disclosed |
| US-8211869-B2 | Methods for cancer therapy and stem cell modulation | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2012-07-03 | — | — | US | disclosed |
| US-20120077841-A1 | METHODS FOR CANCER THERAPY AND STEM CELL MODULATION | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2012-03-29 | — | — | US | disclosed |
| US-8058258-B2 | Methods for cancer therapy and stem cell modulation | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2011-11-15 | — | — | US | disclosed |
| US-8058258-B2 | Methods for cancer therapy and stem cell modulation | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2011-11-15 | — | — | US | disclosed |
| US-20110053882-A1 | METHODS AND COMPOUNDS FOR PREVENTING AND TREATING A TUMOUR | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2011-03-03 | — | — | US | disclosed |
| EP-2217240-A1 | METHODS AND COMPOUNDS FOR PREVENTING AND TREATING A TUMOUR | Agency for Science, Technology And Research (SG) | 2010-08-18 | — | — | EP | disclosed |
| US-20100075915-A1 | METHODS FOR CANCER THERAPY AND STEM CELL MODULATION | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2010-03-25 | — | — | US | disclosed |
| US-20100075915-A1 | METHODS FOR CANCER THERAPY AND STEM CELL MODULATION | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2010-03-25 | — | — | US | disclosed |
| WO-2009058102-A1 | METHODS AND COMPOUNDS FOR PREVENTING AND TREATING A TUMOUR | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2009-05-07 | — | — | WO | disclosed |
| EP-1993553-A1 | METHODS FOR CANCER THERAPY AND STEM CELL MODULATION | Agency for Science, Technology and Research (SG) | 2008-11-26 | — | — | EP | disclosed |
| WO-2007100304-A1 | METHODS FOR CANCER THERAPY AND STEM CELL MODULATION | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2007-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053882-A1 | METHODS AND COMPOUNDS FOR PREVENTING AND TREATING A TUMOUR | HDAC1, CCAR2, HDAC11 | AHCY 340/4885EZH2 929/4885AHCYL1 414/4885 |
| US-20100075915-A1 | METHODS FOR CANCER THERAPY AND STEM CELL MODULATION | MCL1, BCOR, BCL2 | AHCY 2998/4885EZH2 1656/4885AHCYL1 1805/4885 |
| US-20160015693-A1 | METHODS AND COMPOUNDS FOR PREVENTING AND TREATING A TUMOUR | HDAC1, HDAC11, CCAR2 | AHCY 329/4885EZH2 1088/4885AHCYL1 464/4885 |
| US-20120077841-A1 | METHODS FOR CANCER THERAPY AND STEM CELL MODULATION | HCCS, MCL1, AHR | AHCY 1749/4885EZH2 445/4885AHCYL1 1253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.